Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced that the US FDA has granted Fast Track Designation to its allogeneic CAR T-cell therapy, azer-cel, for the treatment of relapsed or refractory diffuse large B-cell lymphoma. …
Imugene's azer-cel granted FDA Fast Track Designation in blood cancer
March 19, 2025 Australian Biotech
Latest Video
New Stories
-
Imugene's azer-cel granted FDA Fast Track Designation in blood cancer
March 19, 2025 - - Australian Biotech -
Island raises $2.72 million through exercise of listed options
March 19, 2025 - - Australian Biotech -
All manufacturers decide to participate in the second cycle of US price negotiation
March 19, 2025 - - Latest News -
Recognition for outstanding results in Medicines Australia’s Continuing Education Program
March 19, 2025 - - Latest News -
Caretaker convention creates PBS uncertainty, at the very least
March 19, 2025 - - Latest News -
Governor-General supports earlier diagnosis and greater awareness of juvenile arthritis
March 18, 2025 - - Latest News -
UK industry in shock over significant increase in payment rate
March 18, 2025 - - Latest News